Dechra Veterinary Products launches Europe’s first transdermal ointment for body weight gain in cats

maandag 1 maart 2021

Dechra Veterinary Products are pleased to announce the launch of Mirataz. Mirataz contains mirtazapine and is the first and only licensed veterinary transdermal ointment for body weight gain in cats experiencing poor appetite and weight loss resulting from chronic medical conditions.

The active ingredient, mirtazapine, addresses reduced appetite and induces significant weight gain in as little as 14 days1. This can allow for a swift response to the initial symptoms, improving condition and wellbeing before you have a definitive diagnosis.

Claire Morgan at Dechra says: ‘Unintended feline weight loss may be associated with serious consequences. Identifying weight loss early, and managing long term, can help improve feline patients’ overall health’.

Mirataz is available in a 5 g tube with innovative child resistant packaging.

For more information about Mirataz visit:


1.Poole M., Quimby J., et al. (2019) A double blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss, Journal of Veterinary Pharmacology and Therapeutics, 42(2) : 179-188